[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetic-kidney-disease-dkd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetic-kidney-disease-dkd":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,76,102,122,144,166,199,221,239],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100613791","phase-2-study-to-assess-the-effects-of-angiopoietin-like-protein-3-angptl3-inhibition-in-adult-participants-with-diabetic-kidney-disease-100613791",false,"NCT07271186","Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease","A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of ANGPTL3 Inhibition With Either Small-Interfering RNA Alone or in Combination With an ANGPTL3 Antibody in Participants With Diabetic Kidney Disease","ANCHOR-POC","Key Inclusion Criteria:\n\n1. Medical history of type 2 diabetes and receiving medical therapy or lifestyle interventions for glucose management\n2. Hemoglobin A1C (HbA1c) of 6.5 to 10% at screening\n3. eGFR 30 to 90 mL\u002Fmin\u002F1.73 m\\^2 using 2021 Chronic Kidney Disease-Epidemiology Collaboration-Estimated Glomerular Filtration Rate using Creatinine and Cystatin C (CKD-EPI eGFRcr-cys) equation at screening\n4. Albuminuria: Urine Albumin to Creatinine Ratio (UACR) of 500 to 5000 mg\u002Fg at screening\n\nKey Exclusion Criteria:\n\n1. Known medical history or clinical evidence indicative of non-diabetic renal disease\n2. Renal disease that required treatment with systemic immunosuppressive therapy, or a history of dialysis or renal transplant\n3. Medically unstable as assessed by the investigator\n4. Hospitalization (ie, \\>24 hours) within 30 days of the screening visit\n\nNOTE: Other Protocol-Defined Inclusion\u002FExclusion Criteria Apply","ALL","18 Years","80 Years",{"count":21,"type":22},270,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This study is researching experimental drugs called ALN-ANG3 and evinacumab (called \"study drugs\"). The study is focused on participants who have diabetic kidney disease.\n\nThe aim of the study is to see how safe and effective the study drugs are.\n\nThe study is looking at several other research questions, including:\n\n* What side effects may happen from taking the study drug\n* How much study drug is in the blood at different times",[28],"Diabetic Kidney Disease (DKD)",[30,31,32],"Chronic Kidney Disease (CKD)","Type 2 Diabetes","Lipid Management","RECRUITING","2026-06-24",{"date":36,"type":37},"2026-06-26","ACTUAL",{"date":39,"type":37},"2026-01-09",{"date":41,"type":22},"2028-04-07",{"name":43,"class":44},"Regeneron Pharmaceuticals","INDUSTRY",53,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100626373","goal-directed-therapy-to-reduce-kidney-and-cardiovascular-risk-in-diabetic-kidney-disease-gold-standard-100626373","NCT07434791","Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)","GOaL Directed-STrategic Approach With New Disease-modifying theraApies to Reduce Kidney and Cardiovascular Risk in Patients With Diabetic Kidney Disease","GOLD-STANDARD","Inclusion Criteria\n\n1. Age ≥ 18 years\n2. T2DM\n3. CKD (eGFR ≥ 25-60 OR UACR ≥ 30 mg\u002Fg)\n4. High Cardiovascular (CV) Risk: Defined as a history of prior myocardial infarction (MI), stroke, or peripheral artery disease (PAD), or the presence of cardiovascular risk factors, (specifically age 40 years or older and at least one of the following: cholesterol above target (LDL≥1.8 mmol\u002FL OR on cholesterol lowering medication), hypertension (≥130\u002F80 mmHg or on BPLMs), or atrial fibrillation.)\n5. Open to start new medications\n\nExclusion Criteria:\n\n1. Type 1 diabetes\n2. HbA1c ≥10% on screening labs\n3. Serum potassium ≥ 5.2 mmol\u002FL on screening labs\n4. Baseline Blood Pressure (BP) \\\u003C 100\u002F60 mmHg at screening\n5. Treated with new or intensified immunosuppression therapy for new (or relapse\u002Fflare of pre-existing) kidney disease within the last 60 days\n6. Kidney Transplant\n7. Use of ≥3 medication classes: Participants already prescribed three or more of the following classes of medications: RASi, SGLT2i, nsMRA or GLP1RA\n8. Intolerance or allergy to any of RASi, SGLT2i, nsMRA or GLP1RA\n9. Known Heart Failure with Reduced Ejection Fraction (HFrEF)\n10. Current pregnancy, lactation or women of childbearing potential, unless using highly effective contraception",{"count":55,"type":22},100,[57],"NA","GOLD-STANDARD is a pragmatic, open-label pilot randomized controlled trial evaluating the feasibility and safety of early goal-directed Cardio-Kidney-Metabolic (CKM) care compared with usual care in patients with diabetic kidney disease. Participants will be randomized 1:1 and managed by nephrologists.\n\nThe intervention includes structured kidney and cardiovascular risk assessment, early shared decision-making regarding guideline-directed medical therapies, and close monitoring for adverse effects. The usual care group will receive standard clinical management at the discretion of the treating clinician. The study will be conducted in Ontario using existing health care infrastructure.",[28],[61,62,63,64],"diabetes","diabetic kidney disease","cardiovascular risk","Cardio-Kidney-Metabolic (CKM) care","NOT_YET_RECRUITING","2026-05-01",{"date":68,"type":37},"2026-05-07",{"date":70,"type":22},"2026-06",{"date":72,"type":22},"2029-03",{"name":74,"class":75},"Sunnybrook Health Sciences Centre","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100590622","phase-2-safety-and-efficacy-of-mesenchymal-stromal-cells-amimestrocel--in-diabetic-kidney-disease-100590622","NCT06969807","Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease","Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cell (Amimestrocel ) in Patients With Diabetic Kidney Disease","MSC-DKD-001","Inclusion Criteria: -\n\n1. Men and women who are ≥18 and ≤ 80 years old.\n2. Diagnosed with type 2 diabetes mellitus.\n3. Diagnosed with diabetic kidney disease based on renal pathology within the past 10 years.\n4. The 24-hour urine protein quantification is continuously ≥ 3.5 g, or the urine albumin-to-creatinine ratio (UACR) \\> 1000 mg\u002Fg.\n5. The estimated glomerular filtration rate (eGFR) ≥ 15 ml\u002Fmin\u002F1.73m² (calculated according to the CKD-EPI formula).\n6. The blood pressure can be controlled at BP ≤ 160\u002F100 mmHg.\n7. Glycated hemoglobin (HbA1c) \\\u003C 9%.\n8. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Patients with kidney diseases not caused by diabetes mellitus.\n2. Patients who have received treatment with systemic immunosuppressants (such as cyclosporine A, tacrolimus, mycophenolate mofetil, etc.) within 30 days before enrollment and the duration of treatment exceeds one week.\n3. Severe cardiovascular diseases, such as congenital heart diseases, atrial fibrillation, NYHA class Ⅲ-IV, unstable angina pectoris, etc.\n4. A history of cerebral hemorrhage or cerebral infarction within the past six months (except for those with a history of lacunar cerebral infarction without residual limb movement disorders, cognitive and language function disorders).\n5. Patients with severe hyperlipidemia: (serum triglyceride ≥ 6.2 mmol\u002FL, serum low-density lipoprotein cholesterol ≥ 4.1 mmol\u002FL).\n6. Hyperkalemia that cannot be controlled through diet or potassium-lowering treatment.\n7. Patients with active infections of hepatitis B or hepatitis C viruses (the copy number of HBV DNA or HCV RNA exceeds the upper limit of the normal value); patients with active tuberculosis; patients with severe immunodeficiency diseases, human immunodeficiency virus (HIV) infection, etc.\n8. Patients with a history of malignant tumors within the past five years.\n9. Patients with a known history of severe allergy to component blood or blood products, or patients with a history of allergy to heterologous proteins.\n10. Lactating women, or female patients who have a pregnancy plan or an egg donation plan from the start of the study to the follow-up period, and male patients (or their partners) who have a childbearing plan or a sperm donation plan from the start of the study to the follow-up period and are unwilling to take contraceptive measures.\n11. Active infection within one week before enrollment and requiring treatment with intravenous antibiotics.\n12. Patients who have participated in other interventional clinical trials within three months before enrollment.\n13. The research physician deems that the patient's condition is not suitable for participating in this clinical study.",{"count":85,"type":22},120,[25],"This trial is to evaluate the efficacy and safety of umbilical cord-derived mesenchymal stromal cells (Amimestrocel ) in study subjects with progressive diabetic kidney disease (DKD), to investigate whether Amimestrocel can improve renal function or proteinuria of DKD patients.",[28],[90,91],"mesenchymal stromal cells(MSCs)","Diabetic kidney disease (DKD)","2026-03-23",{"date":94,"type":37},"2026-03-27",{"date":96,"type":37},"2025-06-09",{"date":98,"type":22},"2028-05-15",{"name":100,"class":75},"Chinese PLA General Hospital",6,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100618054","finerenone-for-cardiorenal-protection-in-diabetic-ckd-impact-on-renal-function-decline-and-heart-failure-100618054","NCT07326631","Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Diagnosed cases of type 2 diabetes mellitus.\n* Chronic kidney disease with eGFR 25-90 mL\u002Fmin\u002F1.73m² and\u002For UACR ≥30 mg\u002Fg.\n* On stable ACE inhibitor or ARB therapy for at least 4 weeks.\n* Serum potassium ≤4.8 mmol\u002FL.\n* Provided written informed consent.\n\nExclusion Criteria:\n\n* Symptomatic heart failure (NYHA class II-IV).\n* eGFR \\\u003C25 mL\u002Fmin\u002F1.73m² or on maintenance dialysis.\n* Known non-diabetic kidney disease.\n* Recent major cardiovascular event (within 30 days).\n* Serum potassium \\>4.8 mmol\u002FL or history of severe hyperkalaemia.\n* Contraindication or hypersensitivity to finerenone.\n* Pregnancy or lactation.\n* Any condition limiting compliance or follow-up.",{"count":85,"type":22},[57],"To assess the effect of Finerinone on slowing renal function decline and improving cardiovascular outcomes, particularly heart failure risk, in patients with diabetic CKD.",[28,112],"Heart Failure","2025-12-24",{"date":115,"type":37},"2026-01-08",{"date":117,"type":22},"2026-01-01",{"date":119,"type":22},"2026-07-01",{"name":121,"class":75},"College of Physicians and Surgeons Pakistan",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100611469","phase-1-mesenchymal-stem-cells-for-chronic-kidney-diseases-100611469","NCT07240987","Mesenchymal Stem Cells for Chronic Kidney Diseases","A Randomized Controlled Study of Mesenchymal Stem Cells in the Treatment of Chronic Kidney Diseases","Inclusion Criteria:\n\n* Agreement to participate in the trial and provision of signed written informed consent\n* Pathological diagnosis of diabetic nephropathy or hypertensive renal damage\n* 15 ≤ eGFR \\\u003C 60 mL\u002Fmin\u002F1.73m², UACR \\> 300 mg\u002Fg\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Extremely severe anemia (hemoglobin \\\u003C 30 g\u002FL)\n* Received blood product transfusion therapy within 1 month\n* Autosomal dominant or recessive polycystic kidney disease (ADPKD)\n* History of kidney transplant or other solid organ transplant\n* Active systemic or localized infection (e.g., pneumonia, osteomyelitis)\n* Allergy to stem cells themselves or stem cell-related culture medium\n* History of allergic reaction to cell products (e.g., blood transfusion, platelets)\n* History of coagulation disorders (thromboembolism, pulmonary embolism, deep vein thrombosis)\n* History of malignancy or current malignant disease\n* Elevated tumor markers (AFP, CEA, CA199, CA125, etc.)\n* Pregnant women or women with plans for pregnancy within 3 months after MSC therapy\n* Participation in drug-related clinical trials within the past 2 months\n* Any form of drug abuse, mental illness, or other conditions considered by the investigator as potentially affecting the trial's validity or the subject's health",{"count":130,"type":22},32,[132,25],"PHASE1","This study will evaluate the effect of intravenous injection of umbilical cord tissue derived mesenchymal stem cells (UMSCs) on the improvement of renal function in patients with chronic kidney disease (CKD) at stage 3 or 4, with the change of estimated glomerular filtration rate (eGFR) as the primary endpoint, and other changes in renal function laboratory indicators, changes in other organ system function laboratory indicators, and adverse reaction events as secondary endpoints. This trial aims to further evaluate the efficacy and safety of UMCSs in CKD patients, and provide new insights into expanding the clinical treatment strategies, delaying the progression and improving the prognosis of CKD patients.",[135,28,136],"Kidney Disease, Chronic","Hypertensive Nephropathy","2025-12-18",{"date":113,"type":37},{"date":117,"type":22},{"date":141,"type":22},"2027-08-31",{"name":143,"class":75},"The First Affiliated Hospital of Air Force Medicial University",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":165},"100613715","mechanisms-underlying-sglt2i-kidney-effect-in-dkd-progression-100613715","NCT07270198","Mechanisms Underlying SGLT2i Kidney Effect in DKD Progression","Longitudinal Multicentre Clinical Study to Explore the Mechanisms Underlying Kidney Effect of SGLT2i in Diabetic Kidney Disease Patients at Risk of Disease Progression by Multiparametric Renal MRI and Biochemical Markers","PERSONALISEDKD","Inclusion Criteria (to be eligible to participate in this trial, an individual must meet all the following criteria):\n\n* male and female subjects aged ≥ 18 years;\n* written informed consent prior to any study specific procedures\n* type 2 Diabetes Mellitus with DKD\n* CKD stage 1 to 3 (eGFR\\>30 ml\u002Fmin) with moderate or severe risk of renal disease progression (according to KDIGO 2024 CKD guidelines, G1 and G2 with albuminuria \\>300 mg\u002Fg, G3a with albuminuria \\>30 mg\u002Fg, and G3b independently of albuminuria levels)\n* ongoing SGLT2i treatment (e.g. canagliflozin, empagliflozin or dapagliflozin) for at least 1 year and stable RAS inhibitor therapy with ACE inhibitors and\u002For ARBs (or without RAS inhibitors in patients with specific contraindications for this medication)\n\nExclusion Criteria (an individual who meets any of the following criteria will be excluded from participation in this trial):\n\n* Uncontrolled diabetes (glycated hemoglobin (A1C) \\> 8%; 64 mmol\u002Fmol)\n* Contraindications to MRI including claustrophobia, pregnancy or lactating, cardiac pacemakers, or other MRI-incompatible prostheses, or impossibility to perform MRI\n* Any chronic clinical condition (e.g. history of malignancy) other than CKD and related complications that could affect completion of the trial or confound data interpretation\n* Non-diabetic CKD: CKD highly suspected to be related with a different renal condition other than Diabetes Mellitus as the cause of CKD (i.e. glomerular disease, tubulo-interstitial nephritis, microangiopathic thrombotic disease, renovascular\u002Fischemic kidney disease, etc)\n* Active systemic autoimmune diseases\n* Concomitant treatment with steroids or any other immunosuppressive agent\n* Chronic heart failure with New York Heart Association class III-IV at the screening visit\n* Intention to become pregnant in the following 2 years (female patients)\n* Drug or alcohol abuse",{"count":55,"type":22},[57],"This is a multicentre and multi-national non-pharmacological, uncontrolled interventional study conducted in a clinical practice setting in DKD patients with CKD stages 1 to 3 with moderate or severe risk of renal function decline in chronic treatment with SGLT2i.\n\nThe main aim of the study is to assess the independent role of baseline individual mpMRI markers (hemodynamic, oxygenation, microstructure, perfusion, and fat fraction) and biochemical markers of MMP-related pathways (MMP-10 and TIMP-1) in the prediction of chronic eGFR decline in the above mentioned patients who are on chronic SGLT2i therapy.",[28],"2025-11-25",{"date":158,"type":37},"2025-12-08",{"date":160,"type":22},"2026-02",{"date":162,"type":22},"2027-08",{"name":164,"class":75},"Mario Negri Institute for Pharmacological Research",1,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":174,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":23,"phases":177,"briefSummary":178,"conditions":179,"keywords":180,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":198},"100590029","phase-2-efficacy-and-safety-study-of-isuzinaxib-in-subjects-with-dkd-100590029","NCT06962098","Efficacy and Safety Study of Isuzinaxib in Subjects With DKD","A Phase 2b Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Evaluate the Efficacy and Safety of Isuzinaxib in Subjects With Diabetic Kidney Disease","PROMISS-DKD","Inclusion Criteria:\n\n1. Male\u002Ffemale subject aged ≥19 years inclusive at the time of informed consent.\n2. Clinical diagnosis of type 2 diabetes and DKD.\n3. 18.5 kg\u002Fm² \\\u003C body mass index \\\u003C 35 kg\u002Fm².\n4. Stable UACR values prior to screening visit.\n5. UACR between 200 and 3000 mg\u002Fg.\n6. Hemoglobin A1c ≤10% at Screening Visit.\n7. Subject who has been taking unchanged dosage of angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blockers (ARB) medication.\n8. Subject who has been on stable anti-hyperglycemic prior to screening.\n9. Females of childbearing potential\u002Fsexually active males with a partner of childbearing potential: commitment to consistently and correctly use an acceptable method of birth control.\n10. Willing to be under dietary management for diabetes.\n11. Willing to comply with all study procedures and availability for the duration of the study.\n12. Capable of understanding the content of and able voluntarily to provide a signed and dated written informed consent form (ICF) prior to any study procedures.\n\nExclusion Criteria:\n\n1. History of type 1 diabetes mellitus or gestational diabetes.\n2. Subject's renal impairment and\u002For albuminuria is considered to be of origin other than DKD.\n3. History of renal transplant and\u002For plan to undergo a renal transplant during the study.\n4. History of acute kidney injury or renal dialysis.\n5. Subject with uncontrolled blood pressure.\n6. Subject taking immunosuppressant.\n7. Subject with known or suspected hypersensitivity to any components of the APX-115 formulation.\n8. Clinically significant abnormal laboratory findings at screening.\n9. History of drug or alcohol abuse within 1 year prior to screening.\n10. History of any cardiovascular event or cardiovascular procedure planned during the clinical study.\n11. Current or history of New York Heart Association class III or IV heart failure.\n12. Clinically significant electrocardiogram (ECG) abnormalities.\n13. Known significant liver disease.\n14. Subject with active urinary tract infection or has not fully recovered before randomization.\n15. History of malignancy within 5 years prior to screening.\n16. Administration of any investigational product.\n17. Major surgery within 28 days or not fully recovered surgery prior to randomization or major surgery planned during the next 6 months.\n18. Positive hepatitis B surface antigen.\n19. Female subject who is pregnant or breastfeeding.\n20. Other medical history which in the opinion of the Investigator would make the subject unsuitable for participation in the study.\n21. Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study or unable to cooperate because of a language problem or poor mental status.","19 Years",{"count":176,"type":22},186,[25],"This study is a multicenter, double-blinded, randomized, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, PK, and efficacy of Isuzinaxib compared with placebo in subjects with DKD.",[28],[181,182,183,184,185,186,187],"Isuzinaxib","APX-115","NOX","Diabetic Nephropathy","DN","Diabetic Kidney Disease","DKD","2025-07-14",{"date":190,"type":37},"2025-07-18",{"date":192,"type":37},"2025-05-26",{"date":194,"type":22},"2028-06-30",{"name":196,"class":197},"Aptabio Therapeutics, Inc.","INDIV",20,{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":220},"100595619","yiqijiangzhuohuoxuetongluo-method-to-delay-the-occurrence-of-end-stage-renal-disease-in-diabetic-kidney-disease--study2-100595619","NCT07034807","YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study2","Evidence-based Evaluation of Yiqi Jiangzhuo Huoxue Tongluo Method in Delaying the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study 2","Inclusion Criteria:\n\n* 1 In line with the diagnostic criteria of Western medicine type 2 DKD ;\n* 2 18-80 years old, regardless of gender ;\n* 3 30ml \u002F min \u002F 1.73m2 ≤ eGFR \\\u003C 60ml \u002F min \u002F 1.73m2 ( eGFR was calculated according to CKD-EPI formula ) ;\n* 4 In line with the diagnostic criteria of qi deficiency and collateral stasis syndrome in traditional Chinese medicine ;\n* 5 hbA1c between 7-10 % ;\n* 6 uACR ≥ 300mg \u002F g\n* 7 blood pressure ≤ 150 \u002F 90mmHg ;\n* 8 signed the informed consent ;\n\nExclusion Criteria:\n\n* 1 Patients who are currently receiving other traditional Chinese medicines and Chinese patent medicines with DKD therapeutic effects ;\n* 2 combined with other clear renal diseases, such as polycystic kidney disease, glomerulonephritis, renal tumors ;\n* 3 Patients with acute or chronic infection who needed treatment were judged by the researchers not suitable for inclusion in the study ;\n* 4 Patients who participated in any other research drug study and \u002F or received or had received another research drug or intervention treatment ( within one month before signing the informed consent form ) ;\n* 5 patients who were allergic or contraindicated to the planned use of drugs ;\n* 6 There are serious acute or chronic diseases that the major researchers believe may pose an excessive risk to the subjects, including : patients with cardiovascular, cerebrovascular, lung, blood, digestive tract, liver, kidney, neuropsychiatric or infectious diseases ;\n* 7 Patients with a history of immunodeficiency, including patients with other acquired, congenital immunodeficiency diseases, or patients with a history of organ transplantation or planned organ transplantation ;\n* 8 Women with positive pregnancy screening test or lactating or planning to get pregnant in the next 24 months. Female or male patients who were reluctant to use contraception throughout the study period ;\n* 9 patients with a history of malignant tumors within 5 years ;\n* 10 patients with type 1 diabetes ;\n* 11 patients with maintenance dialysis \\> 2 weeks and \u002F or expected maintenance dialysis \\> 8 weeks before treatment and patients who were judged by any researcher not suitable for inclusion in the trial.",{"count":207,"type":22},228,[57],"Using the practical randomized controlled trial designed by Zelen, the subjects were randomly divided into the experimental group and the control group. The experimental group was given the traditional Chinese medicine prescription ' Shenzhuo Decoction ' ( composed of Astragalus membranaceus, Salvia miltiorrhiza, Leech, Raw Rhubarb, Epimedium, Motherwort ) + basic treatment ( including nutrition, lifestyle, hypoglycemic, hypotensive, lipid-lowering, control of other risk factors, etc. ), the control group was given basic treatment, a total of 1 year of drug intervention, followed up for 1 year.",[28],"2025-06-20",{"date":213,"type":37},"2025-06-24",{"date":215,"type":22},"2025-08-01",{"date":217,"type":22},"2028-07-31",{"name":219,"class":75},"Liu Hongfang",5,{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":228,"targetDuration":4,"studyType":230,"phases":4,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":237,"leadSponsor":238,"locationsCount":220},"100595412","yiqijiangzhuohuoxuetongluo-method-to-delay-the-occurrence-of-end-stage-renal-disease-in-diabetic-kidney-disease--study1-100595412","NCT07032116","YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1","Evidence-based Evaluation of Yiqi Jiangzhuo Huoxue Tongluo Method in Delaying the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study 1","Inclusion Criteria:\n\n* 1 in line with Western medicine diagnostic criteria for type 2 diabetic kidney disease ;\n* 2 18-80 years old, regardless of gender ;\n* 3 eGFR \\> 15ml \u002F ( min · 1.73m2 ) ; the eGFR was calculated according to the chronic kidney disease epidemiology collaboration equation ( CKD-EPI ).\n* 4 In line with the diagnostic criteria of qi deficiency and collateral stasis syndrome in traditional Chinese medicine ;\n* 5glycosylated hemoglobin ( HbA1c ) between 7-10 % ;\n* 6 blood pressure ≤ 160 \u002F 100mmHg ;\n* 7 to sign the informed consent ;\n\nExclusion Criteria:\n\n* 1 combined with other clear renal diseases, such as polycystic kidney disease, glomerulonephritis, renal tumor, etc. ;\n* 2 patients with a history of recurrent genitourinary tract infection ;\n* 3 combined with cardiovascular and cerebrovascular, digestive, respiratory, urinary, immune system serious diseases or mental diseases ;\n* 4 currently in pregnancy, lactation, or pregnancy plan women ;\n* 5 Patients with type 1 diabetes.\n* 6 Tumor patients undergoing radiotherapy, chemotherapy or targeted therapy.",{"count":229,"type":22},4472,"OBSERVATIONAL","In order to reduce the clinical demand for kidney dialysis rate of Diabetic Kidney Disease（DKD） patients, a bidirectional cohort study of 4472 patients with DKD (Qi deficiency and collateral stasis syndrome) was carried out based on a preliminary DKD cohort of 13,000 patients. The exposure factor was supplementing and reducing the kidney turbidity-Huoxue Tongluo method represented by the addition and subversion of Shenzhuo prescription, and the incidence of end-stage renal disease was the main therapeutic index. Follow-up was conducted for 2 years",[28],"2025-06-13",{"date":235,"type":37},"2025-06-22",{"date":215,"type":22},{"date":217,"type":22},{"name":219,"class":75},{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":23,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":4},"100566418","remote-ischemic-conditioning-for-the-treatment-of-diabetic-kidney-disease-100566418","NCT06654921","Remote Ischemic Conditioning for the Treatment of Diabetic Kidney Disease","The Safety and Efficacy of Remote Ischemic Conditioning for the Treatment of Diabetic Kidney Disease: a Single-center Double-blinded Randomized Controlled Study","RIC-DKD","Inclusion Criteria:\n\n* History of type 2 diabetes and receiving at least 1 antidiabetic medication\n* CKD at stage G3 or G4 (eGFR = 15-60 mL\u002Fmin\u002F1.73 m2)\n* UACR ≥ 300 mg\u002Fg or urinary albumin excretion rate (UAER) ≥ 300 mg\u002F24 h\n* Patients are cognitively and physically capable and willing to interact with the device and perform self-measurements\n* Ability to withstand 5 full minutes of cuff inflation during prescreening\n\nExclusion Criteria:\n\n* Patients with New York Heart Association Class III or IV congestive heart failure at enrollment\n* Patients with severe illness with an expected lifespan of less than 6 months\n* Patients with a recent history (\\\u003C 6 months) of continuous renal replacement therapy, malignant tumor, myocardial infarction, acute coronary syndrome, stroke, seizure, thrombotic\u002Fthromboembolic event (e.g., deep vein thrombosis or pulmonary embolism), or a cerebrovascular accident\n* Patients with known severe arterial disease of the extremities (ulcers, amputations, known symptomatic peripheral arterial disease)\n* Patients at imminent risk of starting dialysis during the study period\n* Patients residing in a long-term care facility\n* Patients in another interventional trial that could influence the intervention or outcome of this trial",{"count":248,"type":22},60,[57],"Chronic kidney disease (CKD) is a growing epidemic affecting 10% of the population worldwide. Significantly, diabetic kidney disease (DKD) is the main cause of CKD and affects approximately 40% of patients with diabetes. Approximately 10% of patients with early-stage CKD and approximately half of patients with advanced-stage CKD suffer progression to renal failure and require dialysis or transplantation to survive. Moreover, DKD progresses particularly rapidly and has a poor prognosis, accounting for almost 50% of end-stage renal disease (ESRD) cases. Dialysis in particular is a burdensome therapy associated with poor patient outcomes and high societal and economic costs. Clinical studies using RIP have demonstrated protection against ischemic target renal damage in a variety of acute and chronic clinical settings . In the renal setting, RIP performed in dialysis patients is known to abrogate brain, heart and liver ischemia occurring during hemodialysis treatments. RIP may play a role in reducing the incidence of cardiac surgery-associated acute kidney injury. However, whether RIP can improve the renal function of patients with DKD is unclear and is worthy of further study.\n\nOur overarching hypothesis is that RIP, performed in DKD patients, could delay progression to renal failure by abrogating progressive ischemic damage in the failing kidney. The present proposal is a pilot study addressing this hypothesis and is aimed at generating proof-of-concept and feasibility data on the benefits of RIP in patients with DKD.",[28],"2024-10-21",{"date":254,"type":37},"2024-10-23",{"date":256,"type":22},"2025-01",{"date":258,"type":22},"2025-12",{"name":260,"class":75},"Capital Medical University"]